Fabry Disease Pipeline Drugs Market Overview
Fabry Disease Drugs pipeline drugs market research report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects.
Key Targets in the Fabry Disease Pipeline Drugs Market
The key targets in the Fabry Disease pipeline drugs market are Alpha Galactosidase A, Ceramide Glucosyltransferase, Bromodomain Containing Protein 4, and Interleukin 1 Receptor. Alpha Galactosidase A has the highest pipeline products.
Fabry Disease Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Fabry Disease Drugs Pipeline Market
The key MoA in the Fabry Disease Drugs pipeline market are Alpha Galactosidase A Replacement, Alpha Galactosidase A Activator, Ceramide Glucosyltransferase Inhibitor, Bromodomain Containing Protein 4 Inhibitor, and Interleukin 1 Receptor Antagonist. Alpha Galactosidase A Replacement has the highest pipeline products.
Fabry Disease Drugs Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Fabry Disease Pipeline Drugs Market
The key RoA in the Fabry Disease pipeline drugs market are intravenous, oral, and subcutaneous. Intravenous has the highest pipeline products.
Fabry Disease Pipeline Drugs Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Fabry Disease Drugs Pipeline Market
The key molecule types in the Fabry Disease Drugs pipeline market are gene therapy, recombinant enzyme, small molecule, gene-modified cell therapy, biologic, enzyme, fusion protein, and recombinant protein. Gene therapy has the highest pipeline products.
Fabry Disease Drugs Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Fabry Disease Drugs Pipeline Market
The key companies in the Fabry Disease Drugs pipeline market are Chiesi Farmaceutici SpA, M6P Therapeutics, Takeda Pharmaceutical Co Ltd, Yuhan Corp, 4D Molecular Therapeutics Inc, AceLink Therapeutics Inc, and CANbridge Life Sciences Ltd. Chiesi Farmaceutici SpA has the highest pipeline products.
Fabry Disease Drugs Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | Alpha Galactosidase A, Ceramide Glucosyltransferase, Bromodomain Containing Protein 4, and Interleukin 1 Receptor |
| Key MoA | Alpha Galactosidase A Replacement, Alpha Galactosidase A Activator, Ceramide Glucosyltransferase Inhibitor, Bromodomain Containing Protein 4 Inhibitor, and Interleukin 1 Receptor Antagonist |
| Key RoA | Intravenous, Oral, and Subcutaneous |
| Key molecule Types | Gene Therapy, Recombinant Enzyme, Small Molecule, Gene-Modified Cell Therapy, Biologic, Enzyme, Fusion Protein, and Recombinant Protein |
| Key companies | Chiesi Farmaceutici SpA, M6P Therapeutics, Takeda Pharmaceutical Co Ltd, Yuhan Corp, 4D Molecular Therapeutics Inc, AceLink Therapeutics Inc, and CANbridge Life Sciences Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fabry Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Fabry Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fabry Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fabry Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fabry Disease (Genetic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fabry Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fabry Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Stakeholders
Table of Contents
Tables
List of Tables
Number of Products under Development for Fabry Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fabry Disease – Pipeline by 4D Molecular Therapeutics Inc, 2022
Fabry Disease – Pipeline by AceLink Therapeutics Inc, 2022
Fabry Disease – Pipeline by Amicus Therapeutics Inc, 2022
Fabry Disease – Pipeline by Bioasis Technologies Inc, 2022
Fabry Disease – Pipeline by Biosidus SA, 2022
Fabry Disease – Pipeline by CANbridge Life Sciences Ltd, 2022
Fabry Disease – Pipeline by CellGenTech Inc, 2022
Fabry Disease – Pipeline by Chiesi Farmaceutici SpA, 2022
Fabry Disease – Pipeline by Equaly SA, 2022
Fabry Disease – Pipeline by Freeline Therapeutics Holdings Plc, 2022
Fabry Disease – Pipeline by GC Pharma, 2022
Fabry Disease – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Fabry Disease – Pipeline by Idorsia Pharmaceutical Ltd, 2022
Fabry Disease – Pipeline by M6P Therapeutics, 2022
Fabry Disease – Pipeline by Pharming Group NV, 2022
Fabry Disease – Pipeline by Resverlogix Corp, 2022
Fabry Disease – Pipeline by Sangamo Therapeutics Inc, 2022
Fabry Disease – Pipeline by Sanofi, 2022
Fabry Disease – Pipeline by Sigilon Therapeutics Inc, 2022
Fabry Disease – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Fabry Disease – Pipeline by UniQure NV, 2022
Fabry Disease – Pipeline by Yuhan Corp, 2022
Fabry Disease – Dormant Projects, 2022
Fabry Disease – Discontinued Products, 2022
Graphs
List of Figures
Number of Products under Development for Fabry Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022












